- DKK547.10m
- DKK499.72m
- DKK40.29m
Brief: BioPorto Q2 EBIT Loss Extends To DKK 16.5 Mln
Brief: Bioporto To Redraw U.S. Application For Regulatory Clearance Of NGAL Test For Risk Assessment For AKI In Patients Under The Age Of 22
Brief: BioPorto Updates On Decision Regarding FDA Application For Pediatric Clinical Use Of NGAL Test
Brief: Bioporto A/S To Increase Share Capital Through Cash Issue
Brief: Bioporto Q1 EBIT Loss Widens To DKK 17.1 Million
Brief: Bioporto FY EBIT Loss Widens To DKK 41.8 Million
Brief: BioPorto Q3 EBIT Loss Widens To DKK 11.5 Million
Brief: BioPorto Receives Communication From FDA Regarding The NGAL Test
Brief: Bioporto Says Initiates Pivotal Clinical Study With The NGAL Test For Children
Brief: Bioporto Q2 EBIT Rises To DKK 10 Mln
Brief: Bioporto A/S submits FDA application for NGAL test
Brief: Bioporto Q1 EBIT Loss At DKK 12.6 Million
Brief: BioPorto Appoints Ole Larsen New CFO
Brief: Bioporto Receives Intention To Grant For A Divisional NGAL Cutoff Patent In Europe
Brief: Bioporto FY EBIT Loss Widens To DKK 36.5 Million
Brief: Bioporto And Roche Diagnostics Sign A Distribution Agreement For Ngal
Brief: Bioporto gets patent approved by United States Patent and Trademark Office
Brief: Bioporto Q3 EBIT loss widens to DKK 10.7 mln
Brief: Bioporto private placement fully subscribed